Literature DB >> 10517490

Cyclooxygenase-2 is essential for normal recovery from 5-fluorouracil-induced myelotoxicity in mice.

M Lorenz1, H S Slaughter, D M Wescott, S I Carter, B Schnyder, J E Dinchuk, B D Car.   

Abstract

Cyclooxygenase (COX) plays a key regulatory role in prostaglandin synthesis. COX-2 is inducible and is the major isoform of inflammatory cells. COX-2-deficient mice were shown to have normal basal hematopoiesis and hematology. We hypothesized that COX-2 induction plays a role in the recovery phase of 5-fluorouracil (5-FU) induced bone marrow injury, because significant macrophage-driven phagocytic removal of necrotic debris and stromal cell reorganization of repopulating marrow occur after 5-FU induction of bone marrow necrosis. Hematologic recovery was markedly delayed with moderately severe leukopenia, thrombocytopenia and reticulocytopenia compared to heterozygotes on day 8 or 12 in Cox-2-/- mice. Mild anemia was present in 5-FU-treated Cox-2-/- and Cox-2+/- mice on days 8 and 12, which was more severe in Cox-2-/- mice. Cox-2-/- mice had markedly decreased bone marrow cell counts per femur and reduced numbers of erythroid and myeloid colony-forming cells compared to heterozygote mice on days 8 and 12 post 5-FU. Histologic examination of 5-FU-treated Cox-2-/- mice revealed a failure to repopulate the intact marrow stroma with hematopoietic cells. Accelerated erythropoiesis following phenylhydrazine-induced hemolytic anemia, however, was comparable between Cox-2-/- and Cox+/- mice, as were induced levels of renal erythropoietin mRNA. COX-2 induction is likely a central event in the accelerated hematopoiesis following myelotoxic injury, because recovery from 5-FU-induced myeloablation is markedly impaired in Cox-2-/- mice but is normal after phenylhydrazine induction of anemia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10517490     DOI: 10.1016/s0301-472x(99)00087-9

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  22 in total

1.  Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury.

Authors:  Sarah L Brown; Terrence E Riehl; Monica R Walker; Michael J Geske; Jason M Doherty; William F Stenson; Thaddeus S Stappenbeck
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

2.  Reduced systemic bicyclo-prostaglandin-E2 and cyclooxygenase-2 gene expression are associated with inefficient erythropoiesis and enhanced uptake of monocytic hemozoin in children with severe malarial anemia.

Authors:  Samuel B Anyona; Prakasha Kempaiah; Evans Raballah; Gregory C Davenport; Tom Were; Stephen N Konah; John M Vulule; James B Hittner; Charity W Gichuki; John M Ong'echa; Douglas J Perkins
Journal:  Am J Hematol       Date:  2012-06-23       Impact factor: 10.047

3.  A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer.

Authors:  S J Dawson; M Michael; J Biagi; K F Foo; M Jefford; S Y Ngan; T Leong; A Hui; A D Milner; R J S Thomas; J R Zalcberg
Journal:  Invest New Drugs       Date:  2006-10-20       Impact factor: 3.850

4.  Cytopenia induction by 5-fluorouracil identifies thrombopoietic mutants in sensitized ENU mutagenesis screens.

Authors:  Nicole M Anderson; Zorana Berberovic; Elizabeth Berndl; Monica L Bailey; Ann M Flenniken; Lucy R Osborne; S Lee Adamson; Janet Rossant; Chen Wang; Mark D Minden; Kelly M McNagny; Robert F Paulson; Dwayne L Barber; William L Stanford
Journal:  Exp Hematol       Date:  2011-09-14       Impact factor: 3.084

5.  Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.

Authors:  Bryan J Schneider; Gregory P Kalemkerian; Michael J Kraut; Antoinette J Wozniak; Francis P Worden; Daryn W Smith; Wei Chen; Shirish M Gadgeel
Journal:  J Thorac Oncol       Date:  2008-12       Impact factor: 15.609

6.  Chronic infection during placental malaria is associated with up-regulation of cycloxygenase-2.

Authors:  Demba Sarr; Delphine Aldebert; Laurence Marrama; Emilie Frealle; Alioune Gaye; Hamoud O Brahim; Makhtar Niang; Jean Marie Dangou; Odile Mercereau-Puijalon; Jean Yves Lehesran; Ronan Jambou
Journal:  Malar J       Date:  2010-02-09       Impact factor: 2.979

Review 7.  Targeting the eicosanoid pathway in non-small-cell lung cancer.

Authors:  Leora Horn; Michael Backlund; David H Johnson
Journal:  Expert Opin Ther Targets       Date:  2009-05-02       Impact factor: 6.902

Review 8.  Does celecoxib improve the efficacy of chemotherapy for advanced non-small cell lung cancer?

Authors:  Leng-Chen Hou; Fang Huang; Hong-Bin Xu
Journal:  Br J Clin Pharmacol       Date:  2015-11-02       Impact factor: 4.335

9.  Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation.

Authors:  Jonathan Hoggatt; Pratibha Singh; Janardhan Sampath; Louis M Pelus
Journal:  Blood       Date:  2009-03-26       Impact factor: 22.113

10.  Monocytes-macrophages that express α-smooth muscle actin preserve primitive hematopoietic cells in the bone marrow.

Authors:  Aya Ludin; Tomer Itkin; Shiri Gur-Cohen; Alexander Mildner; Elias Shezen; Karin Golan; Orit Kollet; Alexander Kalinkovich; Ziv Porat; Gabriele D'Uva; Amir Schajnovitz; Elena Voronov; David A Brenner; Ron N Apte; Steffen Jung; Tsvee Lapidot
Journal:  Nat Immunol       Date:  2012-09-16       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.